Equities

ChromoGenics AB

ChromoGenics AB

Actions
IndustrialsConstruction and Materials
  • Price (SEK)9.84
  • Today's Change0.00 / 0.00%
  • Shares traded3.94k
  • 1 Year change+10.65%
  • Beta1.7053
Data delayed at least 15 minutes, as of Jun 07 2024 17:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ChromoGenics AB is a Sweden-based company, which develops, manufactures and markets foil-based products with controllable optical properties and conducts related business. The Company’s primary product is ConverLight, which is an electrochromic glass with dynamic solar control properties. This glass enables control of light influx to tone down the light and energy admission in various parts of property or premises. The glass is suitable for new construction, reconstruction and renovation and offers ultraviolet protection that reduces risk of fading interiors. The Company distributes ConverLight to commercial installation companies in Sweden and Norway. The main shareholders in the Company are K-Svets Venture AB and New Energy Solutions II K/S.

  • Revenue in SEK (TTM)10.68m
  • Net income in SEK-53.03m
  • Incorporated2002
  • Employees34.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kakel Max AB (publ)148.83m-734.00k26.74m47.00--0.46954.110.1797-0.2415-0.241548.9818.741.533.107.713,166,681.00-0.75374.20-1.126.3823.5923.77-0.49322.540.7344-0.04020.0368---11.870.4119-84.17-27.2740.79--
ABAS Protect AB103.61m5.41m64.29m43.0011.031.588.490.62050.82530.825315.155.751.222.077.862,354,659.006.378.068.0811.3744.5043.995.224.941.1111.240.3973--15.6614.78-28.7883.49----
ChromoGenics AB10.68m-53.03m65.25m34.00--1.39--6.11-527.22-527.223.697.070.07360.42732.21323,727.30-36.55-41.19-46.25-54.0556.9413.78-496.37-269.060.4561-11.320.6991---25.273.957.85---53.72--
Tulikivi Oyj461.98m34.68m249.50m171.008.541.433.630.54010.05130.05130.68390.30631.081.5214.08182,232.107.875.0110.497.5767.3964.017.264.890.62797.740.35345.892.339.66-22.05--25.25--
Data as of Jun 07 2024. Currency figures normalised to ChromoGenics AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.31%Per cent of shares held by top holders
HolderShares% Held
Storebrand Asset Management ASas of 31 Jan 202420.34k0.31%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.